Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Scientists at the University of Edinburgh have identified a novel therapeutic strategy for the treatment of inflammatory disorders. More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
New surrogate biomarker to monitor the progression of HIV infection and other conditions and diseases associated with immune system activation More
Methods of treating or preventing inflammation associated with an autoimmune disorder, particularly inflammatory bowel disease, via administration of muramyl peptide More
Your selection
Browse By
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us